Bud and Yvonne
Diagnosed with chronic myeloid leukemia (CML), Bud noticed an article in the newspaper on Brian Druker's research. Bud and his wife Yvonne contacted Druker in 1996, and Bud was the first patient to receive the drug STI-571 (Gleevec) in clinical trials.
chronic myeloid leukemia,brian druker,drug sti,recovery thanks,gleevec,cml,yvonne,bud,leukemia,clinical trials
- ID: 15712
- Source: DNALC.DNAi
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Brian Druker is a professor at Oregon Health Sciences University.
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
Yvonne talks about the magic pills Bud took.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
Brian Druker talks about how the drug he designed targets the molecular cause of CML.